According to a recent LinkedIn post from All G, the company has been awarded $1.1 million from the New South Wales Government Biosciences Fund to support its work on human milk proteins. The post indicates that the capital will be directed toward advancing human beta-casein technology from laboratory development to proof-of-concept scale-up, regulatory preparation, and eventual manufacturing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The funding, as described in the post, suggests external validation of All G’s precision fermentation approach and may help de-risk early technical and regulatory milestones. For investors, this development could improve the company’s prospects for future commercialisation in the alternative dairy and infant nutrition markets, while potentially positioning All G more competitively in Australia’s emerging biotechnology and food-tech ecosystem.